(Q37217466)

19 August 2017

1 reference

title

Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting (English)

1 reference

19 August 2017

1 reference

1 reference

David J Gallagher

1

1 reference

19 August 2017

Matthew I Milowsky

series ordinal

2

1 reference

19 August 2017

Dean F Bajorin

series ordinal

3

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

113

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

1284-1293

1 reference

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

The treated natural history of high risk superficial bladder cancer: 15-year outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Metastases from transitional cell carcinoma of urinary bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Progress in treatment of advanced urothelial tract tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Chemotherapy in the management of bladder tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Overview of bladder cancer trials in the European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Gemcitabine in transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

The progress and promise of molecular imaging probes in oncologic drug development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23692

7 January 2021

Identifiers

DOI

10.1002/CNCR.23692

1 reference

19 August 2017

1 reference